LIPIKIND F TAB

About

LIPIKIND F TAB is a combination lipid-modifying medication containing Atorvastatin, an HMG-CoA reductase inhibitor (statin), and Fenofibrate, a fibric acid derivative. Atorvastatin primarily reduces the synthesis of cholesterol in the liver, leading to significant reductions in low-density lipoprotein cholesterol (LDL-C) and triglycerides, while also modestly increasing high-density lipoprotein cholesterol (HDL-C). Fenofibrate primarily acts by activating peroxisome proliferator-activated receptor alpha (PPARα), which enhances the catabolism of triglyceride-rich lipoproteins and increases HDL-C production. This dual-action therapy is specifically designed for the comprehensive management of mixed dyslipidemia, where patients present with elevated triglycerides and high LDL-C. The synergistic effects of Atorvastatin and Fenofibrate provide a more potent reduction in atherogenic lipids and an increase in protective lipids, thereby significantly reducing the overall cardiovascular risk in high-risk individuals.

Uses

• Treatment of mixed dyslipidemia
• Management of hypertriglyceridemia
• Reduction of hypercholesterolemia
• Prevention of cardiovascular events in high-risk patients

Directions For Use

Take orally, usually once daily, with or without food, as directed by your doctor.

Benefits

• Comprehensive lipid control
• Significant reduction in LDL-C and triglycerides
• Increase in HDL-C
• Reduced risk of cardiovascular disease
• Synergistic action
• Improved patient compliance (combination)

Side Effects

• Muscle pain (myalgia)
• Liver enzyme elevation
• Nausea
• Abdominal pain
• Diarrhea
• Headache
• Fatigue
• Pancreatitis (rare)
• Gallstones (rare)
• Rhabdomyolysis (rare)
• Rash
• Dyspepsia

Safety Measures

• Alcohol - Avoid excessive alcohol consumption as it can increase the risk of liver damage, especially with statins.
• Pregnancy - Contraindicated due to potential fetal harm.
• Breastfeeding - Contraindicated; do not use while breastfeeding.
• Liver - Contraindicated in active liver disease or unexplained persistent elevations of serum transaminases.
• Kidney - Use with caution in patients with renal impairment; dosage adjustment may be necessary, and fenofibrate is contraindicated in severe renal impairment.
• Lung - Generally safe, but monitor for unexplained shortness of breath or cough, which could indicate rare interstitial lung disease with fibrates.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.